

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 028622/0102

In re patent application of:

Bernd DÖRKEN et al.

Serial No.: 09/673,735

Group Art Unit: 1653

Int'l Filing Date: 04/21/1999

Examiner: Unassigned

Int'l App. No.: PCT/EP99/02693

For: NOVEL CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF

AMOT
 8/9/02
 #10

SECOND PRELIMINARY AMENDMENTCommissioner for Patents
Washington, D.C. 20231

Sir:

Preliminary to examination please amend the above-identified application as follows:

IN THE SPECIFICATION:

On page 9, delete the 1st full paragraph, and replace this paragraph with the following in accordance with 37 CFR §1.121. A marked up version showing changes is attached:

In a particularly preferred embodiment of the present invention said polypeptide linker in the polypeptide of the invention comprises 5 amino acids. As demonstrated in the appended examples, said polypeptide linker advantageously comprises the amino acid sequence Gly Gly Gly Gly Ser (SEQ ID NO:11).

On page 13, delete the 3rd full paragraph, and replace this paragraph with the following in accordance with 37 CFR §1.121. A marked up version showing changes is attached:

In addition, said polypeptide sequence capable of selective binding to a solid support can be a positively or a negatively charged amino acid sequence, a cysteine-containing amino acid sequence, avidin, streptavidin, a functional fragment of Staphylococcus protein A, GST, a His-tag, a FLAG-tag or Lex A. As is described in the appended Examples, the polypeptide of the invention exemplified by a single-chain antibody has also been expressed with an N-